Join to View Full Profile
1365 Clifton Rd NEAtlanta, GA 30322
Phone+1 404-778-1900
Fax+1 404-778-3002
Dr. Carlisle is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jennifer Carlisle is an oncologist in Atlanta, GA and is affiliated with multiple hospitals in the area, including Emory University Hospital and Emory University Hospital Midtown. She received her medical degree from University of Florida College of Medicine and has been in practice 6 years. She specializes in thoracic cancer and is experienced in carcinoid tumors of the lung, thymoma, small cell lung cancer, non-small cell lung cancer, and malignant pleural mesothelioma.
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2016 - 2019
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2011 - 2014
University of Florida College of MedicineClass of 2011
Certifications & Licensure
GA State Medical License 2015 - 2026
MO State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Alpha omega alpha medical honor society, junior year University of Florida College of Medicine, 2010
- University Scholar Four Year Scholar, Valedectorian University of Florida, 2007
Clinical Trials
- Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer Start of enrollment: 2021 Jan 22
Publications & Presentations
PubMed
- Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer.Changfa Shu, Jianfeng Li, Jin Rui, Dacheng Fan, Qiankun Niu
Nature Communications. 2025-03-08 - Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer.Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, Ramaswamy Govindan, Liza C Villaruz
Clinical Cancer Research. 2025-02-03 - Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated...Jacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, Kelly G Paulson, Hossein Borghaei
Cancer. 2025-02-01
Press Mentions
R. Donald Harvey III, PharmD, on Vanguard Oncopharmacology in Lung CancerOctober 8th, 2021
Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer MeetingFebruary 20th, 2020
OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerJune 25th, 2019
Professional Memberships
- Member
- SITCMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
